These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 32779863

  • 1. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Koné-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C.
    Arthritis Rheumatol; 2021 Jan; 73(1):151-161. PubMed ID: 32779863
    [Abstract] [Full Text] [Related]

  • 2. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC.
    Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
    [Abstract] [Full Text] [Related]

  • 3. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
    Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
    Clin Drug Investig; 2011 May; 31(3):191-9. PubMed ID: 21456105
    [Abstract] [Full Text] [Related]

  • 4. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
    J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 15; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 6. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 15; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 7. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
    Yang J, Jain S, Capparelli EV, Best BM, Son MB, Baker A, Newburger JW, Franco A, Printz BF, He F, Shimizu C, Hoshino S, Bainto E, Moreno E, Pancheri J, Burns JC, Tremoulet AH.
    J Pediatr; 2022 Apr 15; 243():173-180.e8. PubMed ID: 34953816
    [Abstract] [Full Text] [Related]

  • 8. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 15; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 9. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
    Ebata R, Yasukawa K, Nagai K, Saito Y, Higashi K, Homma J, Takada N, Takechi F, Saito N, Kobayashi H, Okunushi K, Hamada H, Kohno Y, Hanaoka H, Shimojo N.
    Pediatr Int; 2019 May 15; 61(5):438-443. PubMed ID: 30916859
    [Abstract] [Full Text] [Related]

  • 10. Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
    Cattalini M, Della Paolera S, Zunica F, Bracaglia C, Giangreco M, Verdoni L, Meini A, Sottile R, Caorsi R, Zuccotti G, Fabi M, Montin D, Meneghel A, Consolaro A, Dellepiane RM, Maggio MC, La Torre F, Marchesi A, Simonini G, Villani A, Cimaz R, Ravelli A, Taddio A, Rheumatology Study Group of the Italian Pediatric Society.
    Pediatr Rheumatol Online J; 2021 Mar 16; 19(1):29. PubMed ID: 33726806
    [Abstract] [Full Text] [Related]

  • 11. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Mar 16; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr 16; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 13. Ulinastatin therapy in kawasaki disease.
    Iwashima S, Seguchi M, Matubayashi T, Ohzeki T.
    Clin Drug Investig; 2007 Apr 16; 27(10):691-6. PubMed ID: 17803344
    [Abstract] [Full Text] [Related]

  • 14. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
    J Pediatr; 2006 Sep 16; 149(3):336-341. PubMed ID: 16939743
    [Abstract] [Full Text] [Related]

  • 15. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
    Downie ML, Manlhiot C, Collins TH, Chahal N, Yeung RSM, McCrindle BW.
    Int J Cardiol; 2017 Jun 01; 236():157-161. PubMed ID: 28089146
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
    Clin Exp Med; 2019 May 01; 19(2):173-181. PubMed ID: 30617865
    [Abstract] [Full Text] [Related]

  • 17. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 18. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 May 15; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 19. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 15; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 20. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
    Dionne A, Burns JC, Dahdah N, Tremoulet AH, Gauvreau K, de Ferranti SD, Baker AL, Son MB, Gould P, Fournier A, Newburger JW, Friedman KG.
    Pediatrics; 2019 Jun 15; 143(6):. PubMed ID: 31048414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.